Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis

Intensive chemotherapy is the backbone of induction treatment in patients with acute myeloid leukemia (AML). However, AML patients with concomitant cardiac disease may not be eligible for anthracycline-based therapies. In a small cohort of patients, we have previously shown that anthracycline-free,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuron, David, Pohlmann, Alexander, Angenendt, Linus, Kessler, Torsten, Mesters, Rolf, Berdel, Wolfgang E., Stelljes, Matthias, Lenz, Georg, Schliemann, Christoph, Mikesch, Jan-Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998561/
https://www.ncbi.nlm.nih.gov/pubmed/36749402
http://dx.doi.org/10.1007/s00277-023-05111-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998561/
https://www.ncbi.nlm.nih.gov/pubmed/36749402
http://dx.doi.org/10.1007/s00277-023-05111-x

Ejemplares similares